<p>Lazard Asset Management LLC 在最近向證券交易委員會提交的 13F 表格中披露，在第四季度將其在 Elanco Animal Health Incorporated (NYSE:ELAN - 免費報告) 的持倉增加了 644.3%。該基金在季度內購買了額外的 25,109 股後，持有該公司 29,006 股股票。根據其最新的 SEC 文件，Lazard Asset Management LLC 在 Elanco Animal Health 的持股價值為 350,000 美元。</p>
<p>獲取 <strong>Elanco Animal Health</strong> 警報：</p>
<ul>
<li>看漲還是看跌？評估動物健康護理股票</li>
</ul>
<p>其他一些大型投資者最近也對該公司的持倉進行了調整。CoreCap Advisors LLC 在第四季度購買了價值 29,000 美元的 Elanco Animal Health 新股份。Jones Financial Companies Lllp 在第四季度將其在 Elanco Animal Health 的持股增加了 95.6%。Jones Financial Companies Lllp 目前持有該公司 4,212 股股票，價值 51,000 美元，此前在上個季度又購買了 2,059 股。SRS Capital Advisors Inc. 在第四季度將其在 Elanco Animal Health 的持股增加了 221.2%。SRS Capital Advisors Inc. 目前持有該公司 4,953 股股票，價值 60,000 美元，此前在上個季度又購買了 3,411 股。MRP Capital Investments LLC 在第四季度購買了價值約 61,000 美元的 Elanco Animal Health 新股份。最後，Blue Trust Inc. 在第四季度將其在 Elanco Animal Health 的持倉增加了 47.7%。Blue Trust Inc. 目前持有該公司 5,862 股股票，價值 71,000 美元，此前在此期間又收購了 1,894 股。機構投資者持有該公司 97.48% 的股票。</p>
<h2>分析師評級調整</h2>
<p>一些股票分析師最近對該股票進行了評論。摩根士丹利在 2 月 26 日的研究報告中將 Elanco Animal Health 的目標股價從 14.00 美元下調至 13.00 美元，並對該股票給予了 “持平” 的評級。瑞銀集團在 2 月 26 日的報告中將 Elanco Animal Health 的目標股價從 18.00 美元下調至 17.00 美元，並對該股票給予了 “買入” 的評級。Stifel Nicolaus 在週一將 Elanco Animal Health 的目標股價從 15.00 美元上調至 16.00 美元，並給予該公司 “買入” 評級。巴克萊在 2 月 26 日的研究報告中將 Elanco Animal Health 的目標股價從 20.00 美元下調至 19.00 美元，並對該公司給予了 “超配” 的評級。最後，派珀桑德勒在 3 月 6 日的研究報告中將 Elanco Animal Health 的目標股價從 16.00 美元下調至 12.00 美元，並對該股票給予了 “中性” 評級。四位股票研究分析師對該股票給予了持有評級，三位給予了買入評級。根據 MarketBeat.com，該公司目前的共識評級為 “持有”，平均目標股價為 15.17 美元。</p>
<ul>
<li>Zoetis 宣佈新股息，暗示被低估</li>
</ul>
<p><strong>查看我們關於 ELAN 的最新研究報告</strong></p>
<h2>Elanco Animal Health 的內部活動</h2>
<p>在相關消息中，董事 Lawrence Erik Kurzius 於 3 月 11 日星期二收購了 10,000 股該股票。該股票的平均收購成本為每股 10.20 美元，總交易額為 102,000.00 美元。交易完成後，該董事目前直接持有該公司 111,459 股股票，價值 1,136,881.80 美元。這筆交易代表了他們持股的 9.86% 增加。該交易已在與證券交易委員會的法律文件中披露，相關文件可通過此超鏈接獲取。當前 0.89% 的股票由內部人士持有。</p>
<h2>Elanco Animal Health 的價格表現</h2>
<ul>
<li>2 只具有重大上行潛力的逆向股票推薦</li>
</ul>
<p>NYSE:ELAN 的股票在週五開盤價為 12.68 美元。該公司有 50 日移動平均線為 10.30 美元，200 日移動平均線為 11.46 美元。Elanco Animal Health Incorporated 的 12 個月低點為 8.02 美元，12 個月高點為 18.80 美元。該公司的流動比率為 2.55，速動比率為 1.31，債務與股本比率為 0.66。該股票的市值為 63 億美元，市盈率為 31.70，市盈增長比率為 2.50，貝塔值為 1.49。</p>
<p>Elanco Animal Health (NYSE:ELAN - 獲取免費報告) 最近於 5 月 7 日宣佈了其季度財報。該公司報告季度每股收益為 0.37 美元，超出市場共識預期的 0.31 美元，超出幅度為 0.06 美元。Elanco Animal Health 的淨利潤率為 4.60%，股本回報率為 6.78%。該公司在本季度的收入為 11.9 億美元，而市場共識預期為 11.7 億美元。在去年同期，該公司每股收益為 0.34 美元。該公司的收入同比下降了 1.0%。平均而言，股票研究分析師預測 Elanco Animal Health Incorporated 在當前財年將發佈 0.91 美元的每股收益。</p>
<h2>Elanco Animal Health 公司簡介</h2>
<p>(免費報告)</p>
<p>Elanco Animal Health Incorporated 是一家動物健康公司，創新、開發、生產和銷售寵物和農場動物的產品。它提供寵物健康疾病預防產品，如驅蟲劑和疫苗產品，保護寵物免受蠕蟲、跳蚤和蜱蟲的侵害，品牌包括 Seresto、Advantage、Advantix 和 Advocate；針對犬貓的疼痛、骨關節炎、耳部感染、心血管和皮膚病等適應症的寵物健康治療產品，品牌包括 Galliprant 和 Claro；用於家禽和水產養殖生產的疫苗、抗生素、驅蟲劑及其他產品，以及營養健康產品，包括酶、益生菌和益生元；以及用於反芻動物和豬生產的一系列疫苗、抗生素、植入物、驅蟲劑及其他產品，品牌包括 Rumensin 和 Baytril。</p>
<h2>精選故事</h2>
<ul>
<li>我們更看好的五隻股票，而非 Elanco Animal Health</li>
<li>最佳 ESG 股票：11 只最佳 ESG 投資股票</li>
<li>Joby 股票的波動：近期下跌背後的原因是什麼？</li>
<li>CD 計算器：定期存款計算器</li>
<li>為什麼嘉年華可能是終極非科技增長股票</li>
<li>交易暫停解釋</li>
<li>超微計算機股票因沙特訂單而開闢新高的路徑</li>
</ul>
<p><strong>想看看其他對 ELAN 感興趣的對沖基金持有什麼嗎？</strong> 訪問 HoldingsChannel.com 獲取 Elanco Animal Health Incorporated (NYSE:ELAN - 免費報告) 的最新 13F 文件和內部交易。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUVMQU4?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUVMQU4"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。請將任何問題或意見發送至 contact@marketbeat.com.</em></p>
<h2>你現在應該投資 1,000 美元在 Elanco Animal Health 嗎？</h2>
<p>在你考慮 Elanco Animal Health 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前... 而 Elanco Animal Health 並不在名單上。</p>
<p>雖然 Elanco Animal Health 目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

ELAN

<p>Lazard Asset Management LLC 在第四季度將其在 Elanco Animal Health (NYSE:ELAN) 的持股增加了 644.3%，收購了 25,109 股，使其總持股達到 29,006 股，價值 350,000 美元。其他投資者也調整了他們的持倉，機構持股比例為 97.48%。分析師對該股票的評級意見不一，普遍評級為 “持有”，平均目標價為 15.17 美元。Elanco 的股票開盤價為 12.68 美元，12 個月的價格區間為 8.02 至 18.80 美元。該公司報告第一季度每股收益為 0.37 美元，超出預期</p>

<p>Lazard Asset Management LLC grew its position in Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) by 644.3% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 29,006 shares of the company's stock after purchasing an additional 25,109 shares during the quarter. Lazard Asset Management LLC's holdings in Elanco Animal Health were worth $350,000 as of its most recent SEC filing.</p>
<div class="lb-trans"><p>Lazard Asset Management LLC 在最近向證券交易委員會提交的 13F 表格中披露，在第四季度將其在 Elanco Animal Health Incorporated (NYSE:ELAN - 免費報告) 的持倉增加了 644.3%。該基金在季度內購買了額外的 25,109 股後，持有該公司 29,006 股股票。根據其最新的 SEC 文件，Lazard Asset Management LLC 在 Elanco Animal Health 的持股價值為 350,000 美元。</p>
</div><p>Get <strong>Elanco Animal Health</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Elanco Animal Health</strong> 警報：</p>
</div><ul>
<li>Bullish or Bearish? Vetting Animal Health Care Stocks</li>
</ul>
<div class="lb-trans"><ul>
<li>看漲還是看跌？評估動物健康護理股票</li>
</ul>
</div><p>A number of other large investors also recently made changes to their positions in the company. CoreCap Advisors LLC bought a new stake in Elanco Animal Health in the 4th quarter valued at $29,000. Jones Financial Companies Lllp lifted its holdings in shares of Elanco Animal Health by 95.6% during the fourth quarter. Jones Financial Companies Lllp now owns 4,212 shares of the company's stock worth $51,000 after buying an additional 2,059 shares in the last quarter. SRS Capital Advisors Inc. lifted its holdings in shares of Elanco Animal Health by 221.2% during the fourth quarter. SRS Capital Advisors Inc. now owns 4,953 shares of the company's stock worth $60,000 after buying an additional 3,411 shares in the last quarter. MRP Capital Investments LLC bought a new stake in shares of Elanco Animal Health in the fourth quarter valued at about $61,000. Finally, Blue Trust Inc. boosted its position in shares of Elanco Animal Health by 47.7% in the fourth quarter. Blue Trust Inc. now owns 5,862 shares of the company's stock valued at $71,000 after acquiring an additional 1,894 shares during the period. Institutional investors own 97.48% of the company's stock.</p>
<div class="lb-trans"><p>其他一些大型投資者最近也對該公司的持倉進行了調整。CoreCap Advisors LLC 在第四季度購買了價值 29,000 美元的 Elanco Animal Health 新股份。Jones Financial Companies Lllp 在第四季度將其在 Elanco Animal Health 的持股增加了 95.6%。Jones Financial Companies Lllp 目前持有該公司 4,212 股股票，價值 51,000 美元，此前在上個季度又購買了 2,059 股。SRS Capital Advisors Inc. 在第四季度將其在 Elanco Animal Health 的持股增加了 221.2%。SRS Capital Advisors Inc. 目前持有該公司 4,953 股股票，價值 60,000 美元，此前在上個季度又購買了 3,411 股。MRP Capital Investments LLC 在第四季度購買了價值約 61,000 美元的 Elanco Animal Health 新股份。最後，Blue Trust Inc. 在第四季度將其在 Elanco Animal Health 的持倉增加了 47.7%。Blue Trust Inc. 目前持有該公司 5,862 股股票，價值 71,000 美元，此前在此期間又收購了 1,894 股。機構投資者持有該公司 97.48% 的股票。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析師評級調整</h2>
</div><p>A number of equities analysts recently commented on the stock. Morgan Stanley lowered their price target on shares of Elanco Animal Health from $14.00 to $13.00 and set an &#34;equal weight&#34; rating on the stock in a research report on Wednesday, February 26th. UBS Group lowered their target price on shares of Elanco Animal Health from $18.00 to $17.00 and set a &#34;buy&#34; rating on the stock in a report on Wednesday, February 26th. Stifel Nicolaus lifted their price target on shares of Elanco Animal Health from $15.00 to $16.00 and gave the company a &#34;buy&#34; rating in a research report on Monday. Barclays cut their price target on Elanco Animal Health from $20.00 to $19.00 and set an &#34;overweight&#34; rating for the company in a research note on Wednesday, February 26th. Finally, Piper Sandler lowered their price objective on Elanco Animal Health from $16.00 to $12.00 and set a &#34;neutral&#34; rating on the stock in a research note on Thursday, March 6th. Four equities research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of &#34;Hold&#34; and an average price target of $15.17.</p>
<div class="lb-trans"><p>一些股票分析師最近對該股票進行了評論。摩根士丹利在 2 月 26 日的研究報告中將 Elanco Animal Health 的目標股價從 14.00 美元下調至 13.00 美元，並對該股票給予了 “持平” 的評級。瑞銀集團在 2 月 26 日的報告中將 Elanco Animal Health 的目標股價從 18.00 美元下調至 17.00 美元，並對該股票給予了 “買入” 的評級。Stifel Nicolaus 在週一將 Elanco Animal Health 的目標股價從 15.00 美元上調至 16.00 美元，並給予該公司 “買入” 評級。巴克萊在 2 月 26 日的研究報告中將 Elanco Animal Health 的目標股價從 20.00 美元下調至 19.00 美元，並對該公司給予了 “超配” 的評級。最後，派珀桑德勒在 3 月 6 日的研究報告中將 Elanco Animal Health 的目標股價從 16.00 美元下調至 12.00 美元，並對該股票給予了 “中性” 評級。四位股票研究分析師對該股票給予了持有評級，三位給予了買入評級。根據 MarketBeat.com，該公司目前的共識評級為 “持有”，平均目標股價為 15.17 美元。</p>
</div><ul>
<li>Zoetis Declares New Dividend, Hinting At Undervaluation</li>
</ul>
<div class="lb-trans"><ul>
<li>Zoetis 宣佈新股息，暗示被低估</li>
</ul>
</div><p><strong>Check Out Our Latest Research Report on ELAN</strong></p>
<div class="lb-trans"><p><strong>查看我們關於 ELAN 的最新研究報告</strong></p>
</div><h2>Insider Activity at Elanco Animal Health</h2>
<div class="lb-trans"><h2>Elanco Animal Health 的內部活動</h2>
</div><p>In related news, Director Lawrence Erik Kurzius acquired 10,000 shares of the stock in a transaction that occurred on Tuesday, March 11th. The stock was acquired at an average cost of $10.20 per share, for a total transaction of $102,000.00. Following the transaction, the director now directly owns 111,459 shares in the company, valued at $1,136,881.80. This trade represents a 9.86% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is available through this hyperlink. 0.89% of the stock is currently owned by insiders.</p>
<div class="lb-trans"><p>在相關消息中，董事 Lawrence Erik Kurzius 於 3 月 11 日星期二收購了 10,000 股該股票。該股票的平均收購成本為每股 10.20 美元，總交易額為 102,000.00 美元。交易完成後，該董事目前直接持有該公司 111,459 股股票，價值 1,136,881.80 美元。這筆交易代表了他們持股的 9.86% 增加。該交易已在與證券交易委員會的法律文件中披露，相關文件可通過此超鏈接獲取。當前 0.89% 的股票由內部人士持有。</p>
</div><h2>Elanco Animal Health Price Performance</h2>
<div class="lb-trans"><h2>Elanco Animal Health 的價格表現</h2>
</div><ul>
<li>2 Contrarian Stock Picks With Major Upside</li>
</ul>
<div class="lb-trans"><ul>
<li>2 只具有重大上行潛力的逆向股票推薦</li>
</ul>
</div><p>Shares of NYSE:ELAN opened at $12.68 on Friday. The firm has a 50 day moving average of $10.30 and a 200-day moving average of $11.46. Elanco Animal Health Incorporated has a 12 month low of $8.02 and a 12 month high of $18.80. The company has a current ratio of 2.55, a quick ratio of 1.31 and a debt-to-equity ratio of 0.66. The stock has a market capitalization of $6.30 billion, a PE ratio of 31.70, a PEG ratio of 2.50 and a beta of 1.49.</p>
<div class="lb-trans"><p>NYSE:ELAN 的股票在週五開盤價為 12.68 美元。該公司有 50 日移動平均線為 10.30 美元，200 日移動平均線為 11.46 美元。Elanco Animal Health Incorporated 的 12 個月低點為 8.02 美元，12 個月高點為 18.80 美元。該公司的流動比率為 2.55，速動比率為 1.31，債務與股本比率為 0.66。該股票的市值為 63 億美元，市盈率為 31.70，市盈增長比率為 2.50，貝塔值為 1.49。</p>
</div><p>Elanco Animal Health (NYSE:ELAN - Get Free Report) last announced its quarterly earnings data on Wednesday, May 7th. The company reported $0.37 EPS for the quarter, beating the consensus estimate of $0.31 by $0.06. Elanco Animal Health had a net margin of 4.60% and a return on equity of 6.78%. The business had revenue of $1.19 billion during the quarter, compared to the consensus estimate of $1.17 billion. During the same period in the previous year, the business earned $0.34 earnings per share. The company's revenue was down 1.0% on a year-over-year basis. On average, equities research analysts predict that Elanco Animal Health Incorporated will post 0.91 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Elanco Animal Health (NYSE:ELAN - 獲取免費報告) 最近於 5 月 7 日宣佈了其季度財報。該公司報告季度每股收益為 0.37 美元，超出市場共識預期的 0.31 美元，超出幅度為 0.06 美元。Elanco Animal Health 的淨利潤率為 4.60%，股本回報率為 6.78%。該公司在本季度的收入為 11.9 億美元，而市場共識預期為 11.7 億美元。在去年同期，該公司每股收益為 0.34 美元。該公司的收入同比下降了 1.0%。平均而言，股票研究分析師預測 Elanco Animal Health Incorporated 在當前財年將發佈 0.91 美元的每股收益。</p>
</div><h2>Elanco Animal Health Profile</h2>
<div class="lb-trans"><h2>Elanco Animal Health 公司簡介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>(免費報告)</p>
</div><p>Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.</p>
<div class="lb-trans"><p>Elanco Animal Health Incorporated 是一家動物健康公司，創新、開發、生產和銷售寵物和農場動物的產品。它提供寵物健康疾病預防產品，如驅蟲劑和疫苗產品，保護寵物免受蠕蟲、跳蚤和蜱蟲的侵害，品牌包括 Seresto、Advantage、Advantix 和 Advocate；針對犬貓的疼痛、骨關節炎、耳部感染、心血管和皮膚病等適應症的寵物健康治療產品，品牌包括 Galliprant 和 Claro；用於家禽和水產養殖生產的疫苗、抗生素、驅蟲劑及其他產品，以及營養健康產品，包括酶、益生菌和益生元；以及用於反芻動物和豬生產的一系列疫苗、抗生素、植入物、驅蟲劑及其他產品，品牌包括 Rumensin 和 Baytril。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精選故事</h2>
</div><ul>
<li>Five stocks we like better than Elanco Animal Health</li>
<li>Best ESG Stocks: 11 Best Stocks for ESG Investing</li>
<li>Turbulence for Joby Shares: What's Behind the Recent Dip?</li>
<li>CD Calculator: Certificate of Deposit Calculator</li>
<li>Why Carnival Could Be the Ultimate Non-Tech Growth Stock</li>
<li>Trading Halts Explained</li>
<li>Super Micro Computer Stock Clears New Path Higher on Saudi Orders</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，而非 Elanco Animal Health</li>
<li>最佳 ESG 股票：11 只最佳 ESG 投資股票</li>
<li>Joby 股票的波動：近期下跌背後的原因是什麼？</li>
<li>CD 計算器：定期存款計算器</li>
<li>為什麼嘉年華可能是終極非科技增長股票</li>
<li>交易暫停解釋</li>
<li>超微計算機股票因沙特訂單而開闢新高的路徑</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding ELAN?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Elanco Animal Health Incorporated (NYSE:ELAN - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他對 ELAN 感興趣的對沖基金持有什麼嗎？</strong> 訪問 HoldingsChannel.com 獲取 Elanco Animal Health Incorporated (NYSE:ELAN - 免費報告) 的最新 13F 文件和內部交易。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUVMQU4" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=ELAN"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。請將任何問題或意見發送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Elanco Animal Health Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Elanco Animal Health 嗎？</h2>
</div><p>Before you consider Elanco Animal Health, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 Elanco Animal Health 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Elanco Animal Health wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前... 而 Elanco Animal Health 並不在名單上。</p>
</div><p>While Elanco Animal Health currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Elanco Animal Health 目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Lazard 資產管理公司購買了 Elanco Animal Health 公司（紐約證券交易所代碼：ELAN）的 25,109 股股票